United Asset Strategies Inc. Sells 2,099 Shares of Gilead Sciences, Inc. $GILD

United Asset Strategies Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 27,817 shares of the biopharmaceutical company’s stock after selling 2,099 shares during the period. United Asset Strategies Inc.’s holdings in Gilead Sciences were worth $3,084,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new position in Gilead Sciences in the first quarter worth $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC raised its holdings in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 71,500 shares of company stock valued at $8,336,040. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $122.56 on Wednesday. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61. The firm has a market capitalization of $152.07 billion, a P/E ratio of 24.41, a PEG ratio of 0.81 and a beta of 0.32. The company’s fifty day moving average is $116.79 and its two-hundred day moving average is $112.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GILD shares. Wells Fargo & Company lifted their target price on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. BMO Capital Markets raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $128.27.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.